• 1
    Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138: 627-633.
  • 2
    Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107-1119.
  • 3
    Bomford A. Genetics of haemochromatosis. Lancet 2002; 360: 1673- 1681.
  • 4
    Beaton MD, Adams PC. The myths and realities of hemochromatosis. Can J Gastroenterol 2007; 21: 101-104.
  • 5
    Pietrangelo A. Iron chelation beyond transfusion iron overload. Am J Hematol 2007; 82: 1142-1146.
  • 6
    Hicken BL, Tucker DC, Barton JC. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol 2003; 98: 2072-2077.
    Direct Link:
  • 7
    Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006; 107: 3455-3462.
  • 8
    Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica 2006; 91: 1343-1351.
  • 9
    Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873-880.
  • 10
    Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008; 80: 168-176.
  • 11
    Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136: 501-508.
  • 12
    Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 2000; 95: 2776-2779.
  • 13
    Nielsen P, Fischer R, Buggisch P, Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol 2003; 123: 952-953.
  • 14
    Polo-Romero FJ. Intramuscular deferoxamine in hereditary hemochromatosis. Am J Hematol 2006; 81: 225-226.
  • 15
    Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood 2007; 109: 362-364.
  • 16
    Madani TA, Bormanis J. Reversible severe hereditary hemochromatotic cardiomyopathy. Can J Cardiol 1997; 13: 391-394.
  • 17
    Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 1998; 17: 1103-1120.
  • 18
    Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 2008; 27: 2420- 2439.
  • 19
    Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221-230.
  • 20
    Cappellini MD, Porter JB, El-Beshlawy A, Li C-K, Seymour JF, Elalfy M, et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica 2010; 95: 557-566.
  • 21
    European Medicines Agency (EMEA). Deferasirox summary of product characteristics. 2009. Accessed August 2010.
  • 22
    Gattermann N, Zoumbos N, Angelucci E, Drelichman G, Siegel J, Glimm E, et al. Impact on iron removal of dose reduction for non-progressive serum creatinine increases during treatment with the once-daily, oral iron chelator deferasirox (Exjade, ICL670) [Abstract]. Blood 2006; 108:abstract 3824.
  • 23
    Piga A, Fracchia S, Lai ME, Cappellini MD, Lawniczek T, Dong V, et al. Effect of deferasirox on renal haemodynamics in patients with beta-thalassaemia: first interim analysis [Abstract]. Haematologica 2010; 95( Suppl 2):abstract 1798.
  • 24
    Gattermann N, Finelli C, Della Porta M, Fenaux P, Ganser A, Guerci-Bresler A, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010; 34: 1143-1150.
  • 25
    Bennett W, Ponticelli C, Piga A, Kattamis A, Glimm E, Ford J. Summary of long-term renal safety data in transfused patients with secondary iron overload receiving deferasirox (Exjade®, ICL670) [Abstract]. Blood 2006; 108.abstract 3816.
  • 26
    Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004; 103: 2914-2919.
  • 27
    Gurrin LC, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology 2008; 135: 1945-1952.
  • 28
    Olynyk JK, Hagan SE, Cullen DJ, Beilby J, Whittall DE. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc 2004; 79: 309-313.
  • 29
    Pankow JS, Boerwinkle E, Adams PC, Guallar E, Leiendecker-Foster C, Rogowski J, et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. Transl Res 2008; 152: 3-10.
  • 30
    Adams PC. The natural history of untreated HFE-related hemochromatosis. Acta Haematol 2009; 122: 134-139.